Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program
Gothenburg, August 10, 2023 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, today announced the publication of a scientific article in the prestigious journal, Nature Communications, describing the CAR T construct in the ELC-401 program.The publication entitled "Complementarity-determining region clustering may cause CAR-T cell dysfunction"